Yahoo Finance Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)
Seres Therapeutics (NASDAQ:MCRB) First Quarter 2024 Results
Key Financial Results
Net loss: US$40.1m (loss narrowed by 44% from 1Q 2023).
US$0.28 loss per share (improved from US$0.56 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Seres Therapeutics Earnings Insights
Looking ahead, revenue is expected to decline by 31% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 18%.
Performance of the American Biotechs industry.
The company's shares are down 32% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Seres Therapeutics (including 1 which is a bit unpleasant).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
